By Counterforce Health Team in Luxturna (voretigene neparvovec-rzyl) —

Blue Cross Blue Shield Virginia's Coverage Criteria for Luxturna: What Counts as "Medically Necessary"?

Answer Box: Getting Luxturna Covered in Virginia

Blue Cross Blue Shield Virginia requires prior authorization for Luxturna (voretigene neparvovec-rzyl) with documented biallelic RPE65 mutations, retinal viability testing, and treatment at a qualified center. Your fastest path to approval: 1) Order genetic testing immediately if absent, 2) Submit PA with OCT scans showing >100 microns thickness, and 3) Work with a retinal specialist at an approved treatment center. If denied, Virginia's Bureau of Insurance provides external review within 120 days.

Start today: Call your retinal specialist to confirm RPE65 testing and schedule OCT imaging. Contact BCBS Virginia at 800-901-0020 to verify your specific plan's requirements.

Table of Contents

  1. Policy Overview
  2. Indication Requirements
  3. Step Therapy & Exceptions
  4. Required Diagnostics
  5. Site of Care Requirements
  6. Evidence to Support Medical Necessity
  7. Sample Medical Necessity Narrative
  8. Appeals Playbook for Virginia
  9. Common Denial Reasons & Fixes
  10. FAQ

Policy Overview

Blue Cross Blue Shield Virginia (Anthem) covers Luxturna under their specialty drug policies, but requires prior authorization for all members regardless of plan type. The drug falls under HCPCS code J3590 or C9399 and requires careful documentation of medical necessity.

How Policies Apply by Plan Type

Plan Type Prior Auth Required Formulary Status Special Notes
Commercial HMO/PPO Yes Specialty tier Must use qualified center
Medicaid/SCHIP Yes Covered with PA Additional state review may apply
Medicare Advantage Yes Part B coverage Age restrictions may apply

Key Policy Updates: As of July 2024, BCBS Virginia expanded prior authorization requirements for select gene therapy codes. Always verify current requirements through their Prior Authorization Lookup Tool.

Indication Requirements

FDA-Approved Indication

Luxturna is FDA-approved specifically for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. This narrow indication means BCBS Virginia strictly adheres to these criteria—off-label uses are typically excluded.

Required Documentation

  • Genetic confirmation: CLIA-certified lab results showing biallelic RPE65 pathogenic or likely pathogenic variants
  • Clinical diagnosis: ICD-10 codes for inherited retinal dystrophy (H35.50-H35.59)
  • Age requirements: Typically ≥12 months, though some plans specify ≥3 years or <65 years
Note: Single-gene RPE65 testing or comprehensive retinal dystrophy panels from labs like Invitae or Blueprint Genetics are both acceptable.

Step Therapy & Exceptions

Good news: Luxturna typically doesn't require step therapy because it's the only FDA-approved treatment for biallelic RPE65 deficiency. However, BCBS Virginia may require documentation that:

Alternative Treatments Considered

  • Low-vision rehabilitation services
  • Mobility training
  • Vitamin A supplementation (if applicable)
  • Supportive ophthalmologic care

Medical Exception Pathways

If step therapy is imposed, you can request an exception by documenting:

  • Contraindications: Medical reasons why alternatives aren't appropriate
  • Previous failures: Documentation of inadequate response to supportive care
  • Clinical urgency: Progressive vision loss requiring immediate intervention

Required Diagnostics

Retinal Viability Testing

BCBS Virginia requires comprehensive documentation of remaining retinal function:

Test Requirement Documentation Needed
Optical Coherence Tomography (OCT) >100 microns thickness in posterior pole Recent scans with measurements
Visual Field Testing Measurable function within 30° of fixation Perimetry results
Electroretinogram (ERG) Evidence of remaining photoreceptor function Full-field ERG report
Multi-Luminance Mobility Test (MLMT) Baseline function assessment Test results from qualified center

Timing Requirements

  • All diagnostic tests must be completed within 6 months of PA submission
  • OCT scans should be the most recent (within 3 months preferred)
  • Genetic testing can be older if results are definitive

Site of Care Requirements

Qualified Treatment Centers

Luxturna must be administered at Spark Therapeutics-certified centers. Currently, no certified centers operate in Virginia, meaning patients typically travel to nearby states.

Nearest Certified Centers

  • Children's Hospital of Philadelphia (Philadelphia, PA)
  • Penn Medicine Scheie Eye Institute (Philadelphia, PA)
  • Massachusetts Eye and Ear (Boston, MA)

Network Considerations

Contact BCBS Virginia member services at 800-901-0020 to verify:

  • In-network status of your chosen center
  • Out-of-network exceptions if no in-network options exist
  • Travel benefit coverage (if applicable)

Use the Luxturna Specialist Locator to find retinal specialists who can coordinate care and referrals.

Evidence to Support Medical Necessity

Required Clinical Documentation

Your medical necessity letter should reference:

Primary Sources:

  • FDA prescribing information for Luxturna
  • American Academy of Ophthalmology (AAO) guidelines on inherited retinal diseases
  • Clinical trial data (Russell et al., Lancet 2017)

Patient-Specific Evidence:

  • Genetic testing report with biallelic RPE65 mutations
  • Progressive vision loss documentation
  • Functional vision assessments
  • Quality of life impact statements

Citing Guidelines Effectively

When referencing clinical guidelines, be specific:

  • "Per FDA labeling, Luxturna is indicated for patients with confirmed biallelic RPE65 mutations"
  • "AAO Retina Society guidelines support gene therapy for RPE65-associated dystrophies"
  • "Patient meets all inclusion criteria from pivotal Phase 3 trial"

Sample Medical Necessity Narrative

Clinician Corner: Template Letter Structure

Medical Necessity Letter Checklist:

Problem Statement: "[Patient name] is a [age]-year-old with genetically confirmed biallelic RPE65 mutation-associated retinal dystrophy causing progressive vision loss and functional impairment."

Prior Treatments: "Patient has received comprehensive low-vision rehabilitation and supportive care. No alternative FDA-approved treatments exist for this specific genetic condition."

Clinical Rationale: "Luxturna is the only FDA-approved gene therapy for biallelic RPE65 deficiency. Recent OCT imaging shows [specific measurements] confirming adequate retinal viability for treatment."

Guideline Support: "Treatment aligns with FDA prescribing information and AAO recommendations for inherited retinal dystrophies."

Monitoring Plan: "Patient will be treated at [certified center name] with appropriate pre- and post-treatment monitoring per protocol."

Appeals Playbook for Virginia

Internal Appeals Process

If your initial PA is denied:

Level 1: Standard Internal Appeal

  • Timeline: 15-30 days for determination
  • How to file: BCBS Virginia member portal or written request
  • Required documents: Denial letter, additional clinical evidence, provider letter

Level 2: Peer-to-Peer Review

  • Request physician-to-physician discussion
  • Your retinal specialist speaks directly with BCBS medical director
  • Often resolves coverage issues quickly

Virginia External Review Process

If internal appeals fail, Virginia offers robust external review rights:

Eligibility: Denials based on medical necessity, experimental treatment, or similar clinical judgments

Timeline:

  • File within: 120 days of final denial notice
  • Standard review: 45 days for decision
  • Expedited review: 72 hours if health is jeopardized

How to File:

  • Form: Use Form 216-A for standard review
  • Submit to: SCC Bureau of Insurance, P.O. Box 1157, Richmond, VA 23218
  • Fax: 804-371-9915
  • Email: [email protected]
  • Phone: 877-310-6560

Required Documents:

  • Denial letter from BCBS Virginia
  • Medical records supporting necessity
  • Provider recommendation letter
  • Plan terms/policy language
Tip: Virginia's Bureau of Insurance encourages calling before submitting to ensure you have all required documents.

Common Denial Reasons & Fixes

Denial Reason How to Overturn Documents Needed
"Genetic testing not confirmed" Submit CLIA-certified RPE65 results Lab report with biallelic mutations
"Retinal viability not established" Provide comprehensive eye exams OCT, ERG, visual field results
"Not at qualified center" Identify certified treatment site Center certification documentation
"Experimental/investigational" Emphasize FDA approval FDA prescribing information, clinical trial data
"Prior authorization incomplete" Resubmit with all requirements Complete PA form with all attachments

Success Tips from Advocates

From our advocates: In cases we've supported, the strongest appeals combine genetic testing from a reputable lab, recent OCT imaging showing specific retinal measurements, and a detailed letter from a retinal specialist at or affiliated with a certified treatment center. Patients who engage with Spark's patient support services early often have smoother approval processes.

FAQ

How long does BCBS Virginia prior authorization take? Standard PA decisions are typically made within 15 business days. Expedited reviews (for urgent cases) are completed within 72 hours.

What if Luxturna is non-formulary on my plan? Even if non-formulary, BCBS Virginia may cover Luxturna through their formulary exception process if medical necessity is established and no alternatives exist.

Can I request an expedited appeal in Virginia? Yes. If your physician certifies that waiting could jeopardize your health or vision, you can request expedited external review with 72-hour decisions.

Does step therapy apply if I've tried treatments outside Virginia? Previous treatments from other states count toward step therapy requirements. Provide documentation of all prior therapies and their outcomes.

What's the cost if BCBS Virginia denies coverage? Luxturna's list price is approximately $425,000 per eye. Explore manufacturer patient assistance through Spark Generation Patient Services if coverage is denied.

How do I find a retinal specialist familiar with Luxturna? Use the Luxturna Specialist Locator to find experienced providers who can coordinate genetic testing and treatment planning.

When Coverage Gets Complex

For patients and families navigating Luxturna coverage denials, Counterforce Health helps turn insurance rejections into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies, then drafts point-by-point rebuttals aligned with BCBS Virginia's specific requirements. By pulling the right clinical citations and weaving them into appeals that meet procedural standards, Counterforce Health has helped numerous families secure coverage for complex gene therapies like Luxturna.

The system understands Virginia's external review process and can help prepare documentation that meets the Bureau of Insurance's requirements, potentially saving months of back-and-forth with insurers.

Sources & Further Reading

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage policies may vary by plan type and change over time. For personalized assistance with your specific situation, consider working with Counterforce Health or contacting Virginia's Bureau of Insurance Consumer Services at 877-310-6560.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.